Potential modulation on P-glycoprotein and CYP3A by soymilk and miso: In vivo and ex-vivo studies

Yu, Chung-Ping; Hsieh, Ying‐Hen; Lin, Shiuan-Pey; Chi, Ying-Chang; Hariharan, P. C.; Chao, Pei Dawn Lee; Hou, Yu‐Chi

doi:10.1016/j.foodchem.2013.10.058

Cited by 12 publications

(6 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, grapefruit-felodipine interaction was arisen from inhibition on intestinal CYP 3A427. On the contrary, several food - drug interactions such as mulberry-cyclosporine28, resveratrol-cyclosporine29 and soymilk-cyclosporine30, which resulted in decreased blood levels of cyclosporine, were stem from activation on CYP 3A4.…”

Section: Discussionmentioning

confidence: 99%

Oral intake of curcumin markedly activated CYP 3A4: in vivo and ex-vivo studies

Hsieh

Huang

Yang

et al. 2014

Sci Rep

View full text Add to dashboard Cite

Curcumin, a specific secondary metabolite of Curcuma species, has potentials for a variety of beneficial health effects. It is nowadays used as a dietary supplement. Everolimus (EVL) is an immunosuppressant indicated for allograft rejection and cancer therapy, but with narrow therapeutic window. EVL is a substrate of P-glycoprotein (P-gp) and cytochrome P450 3A4 (CYP3A4). This study investigated the effect of coadministration of curcumin on the pharmacokinetics of EVL in rats and the underlying mechanisms. EVL (0.5 mg/kg) was orally administered without and with 50 and 100 mg/kg of curcumin, respectively, in rats. Blood samples were collected at specific time points and EVL concentrations in blood were determined by QMS® immunoassay. The underlying mechanisms were evaluated using cell model and recombinant CYP 3A4 isozyme. The results indicated that 50 and 100 mg/kg of curcumin significantly decreased the AUC0-540 of EVL by 70.6% and 71.5%, respectively, and both dosages reduced the Cmax of EVL by 76.7%. Mechanism studies revealed that CYP3A4 was markedly activated by curcumin metabolites, which apparently overrode the inhibition effects of curcumin on P-gp. In conclusion, oral intake of curcumin significantly decreased the bioavailability of EVL, a probe substrate of P-gp/CYP 3A4, mainly through marked activation on CYP 3A4.

show abstract

Section: Discussionmentioning

confidence: 99%

Oral intake of curcumin markedly activated CYP 3A4: in vivo and ex-vivo studies

Hsieh

Huang

Yang

et al. 2014

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Diet and herbs modulate ABCB1 activities (Table 4 ). Isoflavone-rich foods, such as miso and soymilk, are ABCB1 activators and may reduce drug concentrations [ 33 ]. For example, some soy-derived food items, including soymilk and miso, induce ABCB1 expression and thus reduce intracellular cyclosporine levels.…”

Section: Abcb1 and Dermatological Therapeutic Agentsmentioning

confidence: 99%

ABCB1 in dermatology: roles in skin diseases and their treatment

Weng

Tsai

2021

J Mol Med

View full text Add to dashboard Cite

Adenosine triphosphate–binding cassette subfamily B member 1 (ABCB1), also known as permeability glycoprotein, multidrug-resistant protein 1, or cluster of differentiation 243 (CD243), is a crucial protein for purging foreign substances from cells. The functions of ABCB1 have been investigated extensively for their roles in cancer, stem cells, and drug resistance. Abundant pharmacogenetic studies have been conducted on ABCB1 and its association with treatment responsiveness to various agents, particularly chemotherapeutic and immunomodulatory agents. However, its functions in the skin and implications on dermatotherapeutics are far less reported. In this article, we reviewed the roles of ABCB1 in dermatology. ABCB1 is expressed in the skin and its appendages during drug delivery and transport. It is associated with treatment responsiveness to various agents, including topical steroids, methotrexate, cyclosporine, azathioprine, antihistamines, antifungal agents, colchicine, tacrolimus, ivermectin, tetracycline, retinoid acids, and biologic agents. Moreover, genetic variation in ABCB1 is associated with the pathogenesis of several dermatoses, including psoriasis, atopic dermatitis, melanoma, bullous pemphigoid, Behçet disease, and lichen planus. Further investigation is warranted to elucidate the roles of ABCB1 in dermatology and the possibility of enhancing therapeutic efficacy through ABCB1 manipulation.

show abstract

“…More interestingly, there is a wide overlap between the substrates of CYP3A and MDR1 (van Waterschoot and Schinkel, 2011). Recent studies (van Waterschoot and Schinkel, 2011;Yu et al, 2014) have reported that CYP3A and MDR1 have similar functions in regulating oral drug bioavailability, drug resistance, and drug-drug interaction. This study found that Cyp3a62 expression was significantly lower in the intestine and Cyp3a9 expression was much higher in the liver of male Mdr1a/b (2/2) rats.…”

Section: Downloaded Frommentioning

confidence: 99%

Development and Characterization of MDR1 (Mdr1a/b) CRISPR/Cas9 Knockout Rat Model

Liang

Zhao

et al. 2019

Drug Metabolism and Disposition

View full text Add to dashboard Cite

Clustered regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein-9 nuclease (Cas9) technology is widely used as a tool for gene editing in rat genome site-specific engineering. Multidrug resistance 1 [MDR1 (also known as P-glycoprotein)] is a key efflux transporter that plays an important role not only in the transport of endogenous and exogenous substances, but also in tumor MDR. In this report, a novel MDR1 (Mdr1a/b) doubleknockout (KO) rat model was generated by the CRISPR/Cas9 system without any off-target effect detected. Western blot results showed that MDR1 was completely absent in the liver, small intestine, brain, and kidney of KO rats. Further pharmacokinetic studies of digoxin, a typical substrate of MDR1, confirmed the deficiency of MDR1 in vivo. To determine the possible compensatory mechanism of Mdr1a/b (2/2) rats, the mRNA levels of the CYP3A subfamily and transporter-related genes were compared in the brain, liver, kidney, and small intestine of KO and wild-type rats. In general, a new Mdr1a/b (2/2) rat model has been successfully generated and characterized. This rat model is a useful tool for studying the function of MDR1 in drug absorption, tumor MDR, and drug target validation.

show abstract

Potential modulation on P-glycoprotein and CYP3A by soymilk and miso: In vivo and ex-vivo studies

Cited by 12 publications

References 30 publications

Oral intake of curcumin markedly activated CYP 3A4: in vivo and ex-vivo studies

Oral intake of curcumin markedly activated CYP 3A4: in vivo and ex-vivo studies

ABCB1 in dermatology: roles in skin diseases and their treatment

Development and Characterization of MDR1 (Mdr1a/b) CRISPR/Cas9 Knockout Rat Model

Contact Info

Product

Resources

About